Literature DB >> 11903734

Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis.

K Adachi1, H Fujishiro, T Katsube, M Yuki, M Ono, A Kawamura, M A Rumi, M Watanabe, Y Kinoshita.   

Abstract

BACKGROUND AND AIMS: Nocturnal gastric acid breakthrough (NAB) is defined as an intragastric pH < 4.0 lasting more than 1 h during the night in patients taking a proton pump inhibitor (PPI). Gastroesophageal reflux disease (GERD) patients with nocturnal gastroesophageal acid reflux accompanied by NAB are thought to be refractory to PPI treatment. The aim of this study was to endoscopically identify the patients with predominant nocturnal gastroesophageal acid reflux.
METHODS: The subjects were 37 patients with erosive reflux esophagitis (Los Angeles classification (LA) grade A, 12; B, 10; C, eight; and D, seven cases) and a control group of 20 patients without esophagitis. The results of ambulatory 24 h gastric and esophageal pH monitoring were compared among different grades of esophagitis.
RESULTS: Gastroesophageal reflux during 24 h in patients with high-grade esophagitis was more frequent than for patients with low-grade esophagitis or no esophagitis. Although the length of esophageal acid exposure (percentage time with pH < 4.0) in patients with grade A or without esophagitis was longer in the daytime, that in patients with grades C and D was longer during the night. The reason for the delayed nocturnal acid exposure was the longer nocturnal acid clearance in high-grade reflux esophagitis.
CONCLUSIONS: Nocturnal exposure of the esophagus to acid occurs frequently in patients with LA grades C and D esophagitis. Thus, the existence of NAB with resulting nocturnal acid reflux should be considered when the patient with high-grade esophagitis shows resistance to PPI treatment.

Entities:  

Mesh:

Year:  2001        PMID: 11903734     DOI: 10.1046/j.1440-1746.2001.02617.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  33 in total

1.  Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers.

Authors:  Yu-Cheng Sheng; Kun Wang; Ying-Chun He; Juan Yang; Qing-Shan Zheng
Journal:  Eur J Clin Pharmacol       Date:  2010-09-14       Impact factor: 2.953

2.  Daytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors.

Authors:  Philip Katz; Peter J Kahrilas; David A Johnson; Tore Lind; Kerstin Röhss; Barry Traxler; Vincent Hugo; John Dent
Journal:  Therap Adv Gastroenterol       Date:  2015-11       Impact factor: 4.409

Review 3.  Gastroesophageal reflux disease and sleep disturbances.

Authors:  Yasuhiro Fujiwara; Tetsuo Arakawa; Ronnie Fass
Journal:  J Gastroenterol       Date:  2012-05-17       Impact factor: 7.527

4.  Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia.

Authors:  Yoshikazu Kinoshita; Shunji Ishihara
Journal:  Therap Adv Gastroenterol       Date:  2008-11       Impact factor: 4.409

5.  Acid-suppressive effects of various regimens of omeprazole in Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers: which regimen has the strongest effect?

Authors:  Tomohiko Shimatani; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Susumu Tazuma; Masaki Inoue
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

Review 6.  The relationship between gastroesophageal reflux disease and sleep.

Authors:  Ronnie Fass
Journal:  Curr Gastroenterol Rep       Date:  2009-06

7.  GERD: GERD and insomnia-first degree relatives or distant cousins?

Authors:  Ellen Stein; Philip O Katz
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

8.  Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.

Authors:  Horng-Yuan Lou; Chun-Chao Chang; Ming-Thau Sheu; Ying-Chen Chen; Hsiu-O Ho
Journal:  Eur J Clin Pharmacol       Date:  2008-08-27       Impact factor: 2.953

Review 9.  Advancements in the analysis of esophageal pH monitoring in GERD.

Authors:  Tiberiu Hershcovici; Anita Gasiorowska; Ronnie Fass
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

Review 10.  NERD: an umbrella term including heterogeneous subpopulations.

Authors:  Edoardo Savarino; Patrizia Zentilin; Vincenzo Savarino
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.